TI
CCCC icon

Trexquant Investment’s C4 Therapeutics CCCC Stock Holding History

Trexquant Investment’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-266,159
Closed -$1.52M – 1580
2024
Q3 		$1.52M Buy
266,159
+147,686
+125% +$889K 0.02% 906
2024
Q2 		$547K Sell
118,473
-106,014
-47% -$632K 0.01% 1216
2024
Q1 		$1.83M Buy
+224,487
New +$1.74M 0.04% 690
2022
Q4 		– Sell
-31,512
Closed -$276K – 1399
2022
Q3 		$276K Sell
31,512
-8,930
-22% -$92.7K 0.01% 1067
2022
Q2 		$305K Buy
40,442
+16,806
+71% +$148K 0.01% 1107
2022
Q1 		$573K Sell
23,636
-6,432
-21% -$156K 0.03% 705
2021
Q4 		$968K Buy
+30,068
New +$1.19M 0.06% 402

Other funds holding CCCC

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Trexquant Investment's CCCC Position: Q4 2024 in Review

Trexquant Investment sold out of C4 Therapeutics (CCCC) in Q4 2024, closing a stake of 266,159 shares — an estimated $1.52M sold.

Trexquant Investment first reported a position in CCCC in Q4 2021 and held it in 7 quarters. The position peaked at $1.83M in Q1 2024. 113 funds tracked by Wall St. Rank hold CCCC as of Q4 2024.

  • Trexquant Investment reported no remaining C4 Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Trexquant Investment sold 266,159 C4 Therapeutics shares in Q4 2024, an estimated $1.52M.
  • Trexquant Investment first reported a position in C4 Therapeutics in Q4 2021 and held it in 7 quarters.
  • Trexquant Investment's C4 Therapeutics position peaked at $1.83M in Q1 2024.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2024.

Based on Trexquant Investment's 13F filing for Q4 2024, filed 12 Feb 2025.